Showing 131-140 of 2985 results for "".
Telemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andIs this the Golden Age of Hair Loss Treatment?
https://practicaldermatology.com/programs/practical-dermatology/is-this-the-golden-age-of-hair-loss-treatment/24036/A perfect storm of many new, unrelated scientific developments also has the potential to fundamentally reshape the way we think about a disease or disease group. Dr. Peter C. Friedman believes many recent breakthroughs have profoundly changed how general dermatologists can manage patients with hairDermWireTV: AAD's Diversity Plan, Galderma Acne Data, Nutrafol Pro-Strength Boosters
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aads-diversity-plan-galderma-acne-data-nutrafol-pro-strength-boosters/19903/Kanya Ferguson, MD, FAAD, Chair of the AAD’s Diversity Committee, speaks about the AAD’s new comprehensive, three-year plan focused on Diversity, Equity, and Inclusion. It was approved with unanimous support by the AAD’s Board of Directors. A new survey conducted by Galderma and retinoid brand AklieGraduating from Dermatology Residency into the COVID-19 Job Market
https://practicaldermatology.com/youngmd-connect/resident-resource-center/graduating-from-dermatology-residency-into-the-covid-19-job-market/23437/Third-year dermatology residents are graduating into an uncertain job market. What does the future hold?Get to Know DataDerm
https://practicaldermatology.com/topics/practice-management/get-to-know-dataderm/22067/Practical Dermatology® gets the inside scoop on the AAD's data registry from Marta Van Beek, MD.Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalWhen and How to Review Staff Compensation & Goals
https://practicaldermatology.com/topics/practice-management/when-and-how-to-review-staff-compensation--goals/21130/Don't skip reviews. Provide feedback and recognize good performance.Journal Club: Comparing Recommendations from Different AD Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-comparing-recommendations-from-different-ad-guidelines/24466/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a pediatric dermatologist at Seattle Children's Hospital, about some of the differences in recommendations from the Annals of Allergy, Asthma, and Immunology Joint Task Force AD guidelines, and the Journal of the American Academy of Dermatology (JAADermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisGuselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.